Kanishka Sircar, M.D.

Peer-Reviewed Articles

1. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res 27(11):3265, 2021. PMID: 34074655.
2. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
3. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
4. Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treat Res Commun 27:100349, 2021. e-Pub 2021. PMID: 33725559.
5. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17(12):1529-1554, 2019. PMID: 31805523.
6. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K.. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 Jun 23, 2019. e-Pub 2019. PMID: 31231128.
7. Wang F, Zhang S, Kim TB, Lin YY, Igbal R, Wang Z, Mohanty V, Sircar K, Karam JA, Wendl MC, Meric-Bernstam F, Weinstein JN, Ding L, Mills GB, Chen K.. Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods. 2019 May; 16(5):401-404, 2019. e-Pub 2019. PMID: 30988467.
8. Sekino Y, Sakamoto N, Goto K, Honma R, Shigematsu Y, Quoc TP, Sentani K, Oue N, Teishima J, Kawakami F, Karam JA, Sircar K, Matsubara A, Yasui W. UC 416+A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC Cancer 18(1):952, 2018. e-Pub 2018. PMID: 30286729.
9. Romero Arenas MA, Whitsett TG, Aronova A, Henderson SA, LoBello J, Habra MA, Grubbs EG, Lee JE, Sircar K, Zarnegar R, Scognamiglio T, Fahey TJ, Perrier ND, Demeure MJ. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. Ann Surg Oncol 25(3):801-807, 2018. e-Pub 2017. PMID: 29218429.
10. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and Outcomes of Patients with Renal Medullary Carcinoma: A Multi-Center Collaborative Study. BJU Int 120(6):782-792, 2017. e-Pub 2016. PMID: 27860149.
11. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 123(24):4823-4831, 2017. e-Pub 2017. PMID: 28832979.
12. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape. Clin Cancer Res 23(21):6686-6696, 2017. e-Pub 2017. PMID: 28710314.
13. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies during 3 Decades: Comparison Between the Cytokine (1987 to 2005) and the Targeted Therapy (2006 to 2015) Eras. J Urol 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
14. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer 15(3):363-370, 2017. e-Pub 2017. PMID: 28216278.
15. Wobker SE, Przybycin CG, Sircar K, Epstein JI. Renal Oncocytoma with Vascular Invasion: A Series of 22 Cases. Hum Pathol 58:1-6, 2016. e-Pub 2016. PMID: 27498062.
16. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol 196(3):678-84, 2016. e-Pub 2016. PMID: 27036304.
17. Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol 70(2):348-57, 2016. e-Pub 2016. PMID: 26895810.
18. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RG. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 30(2):363, 2016. PMID: 27505681.
19. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117(5):761-5, 2016. e-Pub 2015. PMID: 26032863.
20. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-97, 2016. e-Pub 2015. PMID: 26364599.
21. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 69(5):866-74, 2016. e-Pub 2015. PMID: 26626617.
22. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol 34(5):237.e19-26, 2016. e-Pub 2015. PMID: 26707613.
23. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2015. PMID: 26206754.
24. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 33(10):427.e17-23, 2015. e-Pub 2015. PMID: 26004164.
25. Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res 75(19):4131-42, 2015. e-Pub 2015. PMID: 26282167.
26. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res 1(4):212-24, 2015. e-Pub 2015. PMID: 27499906.
27. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 3(9):1017-29, 2015. e-Pub 2015. PMID: 26014097.
28. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol 28(9):1225-35, 2015. e-Pub 2015. PMID: 26111976.
29. Vodopivec DM, Habra MA, Ng C, Sircar K, Grubbs EG. Visual Vignette. Endocr Pract 21(7):854, 2015. e-Pub 2015. PMID: 26121444.
30. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw 13(6):772-99, 2015. PMID: 26085393.
31. Hamdi A, Mulanovich VE, Matin SF, Landon G, Sircar K, Tu SM, Nieto Y. Isolated Renal Mucormycosis in a Transplantation Recipient. J Clin Oncol 33(10):e50-1, 2015. e-Pub 2014. PMID: 24821884.
32. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol 33(4):166.e21-9, 2015. e-Pub 2015. PMID: 25700975.
33. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network. Kidney cancer, version 3.2015. J Natl Compr Canc Netw 13(2):151-9, 2015. PMID: 25691606.
34. Shawa H, Elsayes KM, Javadi S, Sircar K, Jimenez C, Habra MA. Clinical and radiologic features of pheochromocytoma/ganglioneuroma composite tumors: a case series with comparative analysis. Endocr Pract 20(9):864-9, 2014. PMID: 24641930.
35. Xu B, Abourbih S, Sircar K, Kassouf W, Aprikian A, Tanguay S, Brimo F. Diagnostic and Prognostic Role of Immunohistochemical Expression of Napsin-A Aspartic Peptidase in Clear Cell and Papillary Renal Cell Carcinoma: A Study Including 233 Primary and Metastatic Cases. Appl Immunohistochem Mol Morphol 22(3):206-12, 2014. e-Pub 2013. PMID: 23702650.
36. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R, Natiomal compresensive cancer networks. Kidney cancer, version 2.2014. J Natl Compr Canc Netw 12(2):175-82, 2014. PMID: 24586079.
37. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169(6):891-9, 2013. e-Pub 2013. PMID: 24086089.
38. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol 31(7):1171-7, 2013. e-Pub 2012. PMID: 22534087.
39. Xu B, Abourbih S, Sircar K, Kassouf W, Mansure JJ, Aprikian A, Tanguay S, Brimo F. Enhancer of Zeste Homolog 2 Expression Is Associated With Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma: A Comparative Study and Review of the Literature. Arch Pathol Lab Med 137(10):1326-1336, 2013. PMID: 24079759.
40. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid Urothelial Carcinomas - A Chemo-sensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. J Urol 189(5):1656-61, 2013. e-Pub 2012. PMID: 23159581.
41. Brimo F, Sircar K, Chevalier S, Saad F, Lacombe L, Têtu B, Scarlata E, Aprikian A. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Cell Tissue Bank 13(4):631-8, 2012. e-Pub 2011. PMID: 22200970.
42. Choucair KA, Guerard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazil L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology 5(6):453-60, 2012. e-Pub 2012.
43. Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, Shariat SF. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 30(5):666-72, 2012. e-Pub 2010. PMID: 20933445.
44. Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [18F]Fluorodeoxyglucose Positron Emission Tomography-Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case. J Clin Oncol 30(26):e246-9, 2012. e-Pub 2012. PMID: 22649135.
45. Shariat SF, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C. Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. Eur Urol 62(2):224-31, 2012. e-Pub 2012. PMID: 22285763.
46. Rink M, Robinson BD, Green DA, Cha Ek, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rious-Leclercq N, Guoc CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. The Journal of Urology 188(2):398-404, 2012. PMID: 22698626.
47. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals Asparagine Synthetase is a target in castration resistant prostate cancer. Am J Pathol 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
48. Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA. Interactions and Relationships of PTEN, ERG, SPINK1 AND AR in Castration Resistant Prostate Cancer. Histopathology 60(4):645-52, 2012. e-Pub 2012. PMID: 22260502.
49. Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire JA. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 51(2):149-60, 2012. e-Pub 2011. PMID: 22045666.
50. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling Lethal Prostate Cancer Variant with Small Cell Carcinoma Features. Clin Cancer Res 18(3):666-77, 2012. e-Pub 2011. PMID: 22156612.
51. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One 7(2):e31259. doi:10.1371/journal.pone.0031259, 2012. e-Pub 2012. PMID: 22363599.
52. Zhang HM, Perrier ND, Grubbs EG, Sircar K, Ye ZX, Lee JE, Ng CS. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol 67(1):38-46, 2012. e-Pub 2011. PMID: 21783181.
53. Abou Youssif T, Fahmy MA, Koumakpayi IH, Ayala F, Al Marzooqi S, Chen G, Tamboli P, Squire J, Tanguay S, Sircar K. The Mammalian Target of Rapamycin Pathway Is Widely Activated Without PTEN Deletion in Renal Cell Carcinoma Metastases. Cancer 117(2):290-300, 2011. e-Pub 2010. PMID: 20830770.
54. Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12(12):1031-40, 2010.
55. Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57(4):575-81, 2010. e-Pub 2009. PMID: 19959276.
56. Al Otaibi M, Abou Youssif T, Alkhaldi A, Sircar K, Kassouf W, Aprikian A, Mulder D, Tanguay S. Renal cell carcinoma with inferior vena caval extention: impact of tumour extent on surgical outcome. BJU Int 104(10):1467-70, 2009. e-Pub 2009. PMID: 19388993.
57. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, Squire JA. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218(4):505-13, 2009. PMID: 19402094.
58. Szymanski KM, Baazeem A, Sircar K, Tanguay S, Kassouf W. Primary renal carcinoid tumour with inferior vena caval tumour thrombus. Can Urol Assoc J 3(3):E7-E9, 2009. PMID: 19543456.
59. Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA, Bismar TA. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 15(4):1376-83, 2009. PMID: 19228738.
60. Aldousari S, Sircar K, Kassouf W. Plasmacytoid urothelial carcinoma of the bladder: a case report. Cases J 2:6647, 2009. e-Pub 2009.
61. Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286-92, 2008. e-Pub 2008. PMID: 18484590.
62. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int 101(10):1302-9, 2008. e-Pub 2008. PMID: 18294307.
63. Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13(23):7044-52, 2007. PMID: 18056181.
64. Mujoomdar A, Maheshwari S, Zand KR, Sircar K, Mesurolle B. Sonographic diagnosis of a ruptured intratesticular pseudoaneurysm secondary to orchitis. AJR Am J Roentgenol 189(1):W20-2, 2007. PMID: 17579129.
65. Sircar K, Gottlieb B, Alvarado C, Aprikian A, Beitel LK, Alam-Fahmy M, Begin L, Trifiro M. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer Prostatic Dis 10(4):360-8, 2007. e-Pub 2007. PMID: 17440439.
66. Binsaleh S, Sircar K, Elhilali M, Anidjar M. BCG for upper-tract transitional-cell carcinoma: is it safe in patients with renal compromise?. J Endourol 20(12):1068-71, 2006. PMID: 17206904.
67. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2):289-98, 2006. PMID: 16752412.
68. Sircar K, Gaboury L, Ouadi L, Mecteau M, Scarlata E, Saad F, Aprikian A, Tanguay S, Lapointe S, Lussier C, Miletti T, Lanoix J. Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens. Clin Cancer Res 12(14 Pt 1):4178-84, 2006. PMID: 16857789.
69. Alvarado C, Beitel LK, Sircar K, Aprikian A, Trifiro M, Gottlieb B. Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res 65(18):8514-8, 2005. PMID: 16166332.
70. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3):804-14, 2005. PMID: 15734935.
71. Binsaleh S, Sircar K, Chan PT. Feasibility of simultaneous testicular microdissection for sperm retrieval and ipsilateral testicular tumor resection in azoospermic men. J Androl 25(6):867-71, 2004. PMID: 15477357.
72. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101(6):1345-56, 2004. PMID: 15316903.
73. Al-Assiri M, Al-Otaibi MF, Sircar K, Laplante M. Renal pelvis squamous cell carcinoma and renal cell carcinoma in a tuberculous kidney. ScientificWorldJournal 4:965-8, 2004. PMID: 15578119.
74. Zakian KL, Eberhardt S, Hricak H, Shukla-Dave A, Kleinman S, Muruganandham M, Sircar K, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology 229(1):241-7, 2003. e-Pub 2003. PMID: 12920178.
75. Yossepowitch O, Sircar K, Scardino PT, Ohori M, Kattan MW, Wheeler TM, Reuter VE. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol 168(5):2011-5, 2002. PMID: 12394697.
76. Huizinga JD, Berezin I, Sircar K, Hewlett B, Donnelly G, Bercik P, Ross C, Algoufi T, Fitzgerald P, Der T, Riddell RH, Collins SM, Jacobson K. Development of interstitial cells of Cajal in a full-term infant without an enteric nervous system. Gastroenterology 120(2):561-7, 2001. PMID: 11159897.
77. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol 156(4):1157-63, 2000. PMID: 10751339.
78. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23(4):377-89, 1999. PMID: 10199467.
79. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10(1):599. e-Pub 2010. PMID: 21044312.
80. Abourbih S, Sircar K, Tanguay S, Kassouf W, Aprikian A, Mansure J, Brimo F. Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study. World J Surg Oncol 11(1):298. e-Pub 2013. PMID: 24266898.
81. Falahkeirkhah K, Guo T, Hwang M, Tamboli P, Wood CG, Karam JA, Sircar K, Bhargava R. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Investigation.
82. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. e-Pub 2021. PMID: 34717797.
83. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. e-Pub 2021. PMID: 34625389.
84. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. e-Pub 2021. PMID: 34301458.
85. Cowman S, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher KM, Maughan BL, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1α is an independent prognostic indicator in kidney cancer. Clin Cancer Res. e-Pub 2020. PMID: 32586940.

Invited Articles

1. Subbiah V, Sircar K. Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. J Natl Compr Canc Netw 17(7):886-888, 2019. PMID: 31319384.
2. Sircar K, Rao P, Jonasch E, Monzon FA, Tamboli P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer 32(1):303-11, 2013. e-Pub 2012. PMID: 23237216.
3. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 2011. PMID: 21707288.

Manuals, Teaching Aids, Other Teaching Publications

1. Sircar K, Begin L. Urologic Pathology Syllabus: McGill Medical School, 2008.

Editorials

1. Sircar K, Navone N, Zhang W, Richards N. Beyond the Abstract - Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Urotoday.com, 2012.

Abstracts

1. Guo T, Li J, Wani K, Murugan P, Brimo F, Lazar A, Tamboli P, Zhang J, Bhat K, Sircar K. Gene Methylation Patterns of Aggressive Chromophobe Renal Cell Carcinoma. Modern Pathology 34(2):559, 2021.
2. Hwang, M, Kerns, BJ, Lee Y, Thompson D, Karam J, Rao P, Tamboli P, Bhat K, Sircar K. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era. Laboratory Investigation 100(1):928, 2020.
3. Oramas, D, Kim, T, Chen, K, Rao, P, Tamboli, P, Karam, J, Shapiro, D, Sircar, K. Response to Immune Checkpoint Therapy and Clinical Outcome is Not Related to Proportion of Sarcomatous Component in Sarcomatoid Renal Cell Carcinoma. Laboratory Investigation 100(1):991, 2020.
4. Akgul, M., Kim, T., Qi, Y., Alouch, N., Murugan, P., Shen, S., Brim, F., Rao, P., Tamboli, P., Chen, K., Sircar, K.. TP53 and PTEN Mutational Status and Outcome Prediction in Chromophobe Renal Cell Carcinoma. Laboratory Investigation 99(1):781, 2019.
5. Tang, S., Akgul, M., Kim, T., Chen, K., Wang, F., Sircar, K.. Manual Estimation of Tumor Purity is Poor Compared to Sequencing Based Estimates. Laboratory Investigation 99(1):1965, 2019.
6. Ma S, Alouch N, Hawkins M, Ruiz-Cordero R, Li L, Kawakami F, Brimo F, Wang J, Tamboli P, Sircar K, Rao P. Aggressive Chromophobe RCC (ChRCC) Molecularly and Immunochemically Separable From Indolent ChRCC. Modern Pathology 31(3):361-362, 2018.
7. Ruiz-Cordero R, Li L, Qi Y, Kawakami F, Alouch N, Lu W., Chen K, Brimo F, Wang,J. Tamboli P, Rao P, Sircar K. Hybrid Oncocytic Renal Tumors Display A Molecular Profile Intermediate Between Oncocytoma And Chromophobe Renal Cell Carcinoma. Modern Pathology 31(3):380-380, 2018.
8. Kawakami F, Sircar K, Tamboli P, Rodriguez-Canales J, Wood C.G, Karam J.A. Immunohistochemical phenotype analysis of a large series of sarcomatoid renal cell carcinoma. Laboratory Investigation(97):235A, 2017.
9. Ruiz-Cordero, Rao, P, Tamboli, P, Singh, R, Routbort, MJ, Sircar, K. Characterization of Driver Mutations in Hybrid Renal Oncocytic Tumors. Laboratory Investigation 97:253A, 2017.
10. Sircar K, Wang, Z, Kim, T, Peng, B, Karam, JA, Creighton, CJ, Chow, C, Rodriguez Canales, J, Tamboli, P, Mills, G, Shaw, K, Chen, K. Sarcomatoid Clear Cell RCC Shows a Distinct Molecular Pathogenesis and Driver Mutation Profile. Laboratory Investigation 96((S1)):262A, 2016.
11. Kawakami F, Sircar K, Rodriguez-Canales J, Tamboli P, Tannir N.M, Jonasch E, Wistuba I.I, Wood C.G, Karam J.A. Expression of PD-1 and PD-L1 in patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). Journal of Clinical Oncology 34(2 SUPPL):1, 2016.

Book Chapters

1. Sircar K and Tamboli P. Renal Mass Biopsy. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1st Edition. Springer, 2020.
2. Guo CC, Zhang M, Sircar K.. Tumors of the Renal Pelvis. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1st Edition. Springer, 2020.
3. Rao P, Perrino CM, Zynger DL, Jorda M, Tamboli P, Sanchez DF, Cubilla AL, Iczkowski K, Zhang M, Sircar K.. Genitourinary Pathology (including adrenal gland). In: Oncological Surgical Pathology. 1st Edition. Springer, 2020.
4. Tamboli P, Sircar K. Renal Cell Carcinoma, Pathologic Considerations. In: Renal Cell Cancer: Principles and Practice. 2nd Edition. Springer, 2015.
5. Tamboli P, Sircar K. Renal Cell Carcinoma, Pathologic Considerations. In: Renal Cell Cancer: Principles and Practice. 1st Edition. Springer, 2011.

Letters to the Editor

1. Huizinga JD, Berezin I, Chorneyko K, Thuneberg L, Sircar K, Hewlett BR, Riddell RH. Interstitial cells of Cajal: pacemaker cells?. Am J Pathol 153: 2008-11, 1998.